Current and Emerging Therapeutic Options in Adrenocortical Cancer Treatment

Table 2

Treatment protocols employed in the FIRM-ACT study.

Berruti and coll. protocol (EDP/M)	Every 28 days
	(i) Day 1	40 mg/m^2	Doxorubicin
	(ii) Day 2	100 mg/m^2	Etoposide
	(iii) Day 3, 4	100 mg/m^2	Etoposide + 40 mg/m^2 cisplatin
	(iv) Daily		Mitotane with a blood level 14–20 mg/L
Khan and e coll. protocol (Sz/M)	Every 21 days
	(i) Day 1–5	1 g	Streptozotocin
	(ii) Subsequently	2 g	Streptozotocin
	(iii) Daily		Mitotane with a blood level 14–20 mg/L